Micro Vascular and Macro Vascular Disease in Systemic Hypertension: The Role of Cardiac Imaging and Nitric Oxide Synthase Gene Polymorphism by Elkilany, Galal E Nagib et al.
Article
Micro Vascular and Macro Vascular Disease in 
Systemic Hypertension: The Role of Cardiac 
Imaging and Nitric Oxide Synthase Gene 
Polymorphism
Elkilany, Galal E Nagib, Ghosbashi, Abeer Saeed, Fedacko, Jan, 
Salama, Mai, Singh, Jaipaul, Elmahal, Mohammed, Allam, Ade H., 
Raafat, Ahmad Adham and Aiash, Hani
Available at http://clok.uclan.ac.uk/31651/
Elkilany, Galal E Nagib, Ghosbashi, Abeer Saeed, Fedacko, Jan, Salama, Mai, Singh, 
Jaipaul ORCID: 0000-0002-3200-3949, Elmahal, Mohammed, Allam, Ade H., Raafat, 
Ahmad Adham and Aiash, Hani (2020) Micro Vascular and Macro Vascular Disease in 
Systemic Hypertension: The Role of Cardiac Imaging and Nitric Oxide Synthase Gene 
Polymorphism. International Journal of Clinical Cardiology and Research, 4 (1). ISSN 
2639-3786  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
Review Article
Micro Vascular and Macro Vascular Disease in 
Systemic Hypertension: The Role of Cardiac Imaging 
and Nitric Oxide Synthase Gene Polymorphism - 
Galal E Nagib Elkilany1*, Abeer Saeed Ghobashi2, Jan Fedacko3, Mai 
Salama4, Jaipaul Singh5, Sherif Baath Allah6, Mohammed Elmahal7, 
Adel H Allam8, Ahmad Adham Raafat9 and Hani Aiash10
1,4Professor and Consultant of Cardiology (SCU), Tanta University, Egypt
2Professor of Radio-Diagnosis, Tanta University, Egypt
3Kosice Medical University, Slovakia
5School of Forensic and Applied Sciences, University of Central Lancashire, Preston, UK
6RAK Medical and Masafi  Hospital; Health Science University, UAE
7London University and Masafi  Hospital, UAE
8Professor of Cardiology, AL-Azhar University, Egypt
9Alexandria University, Alexandria, Egypt
10SUNY Upstate Medical University, Syracuse, NY, USA
*Address for Correspondence: Galal Eldin Nagib Elkilany, Professor of Cardiology-SCU and Consultant 
of Cardiology at Tanta University, ARE, 132 Holly Drive, LaPlace, LA , 70068 , USA, Tel: 973-981-7875; 
ORCID ID: https://orcid.org/0000-0001-8327-7862; E-mail:  
Submitted: 21 January 2020; Approved: 11 February 2020; Published: 13 February 2020
Cite this article: Nagib Elkilany GE, Ghobashi AS, Fedacko J, Salama M, Singh J, et al. Micro 
Vascular and Macro Vascular Disease in Systemic Hypertension: The Role of Cardiac Imaging and 
Nitric Oxide Synthase Gene Polymorphism. Int J Clin Cardiol Res. 2020;4(1): 001-008.
Copyright: © 2020 Nagib Elkilany GE, et al. This is an open access article distributed under 
the Creative Commons Attribution License, which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original work is properly cited.
International Journal of
Clinical Cardiology & Research
ISSN: 2639-3786
SCIRES Literature - Volume 4 Issue 1 - www.scireslit.com Page -002
International Journal of Clinical Cardiology & Research
INTRODUCTION
Hereditary factors contributed directly to the occurrence 
of hypertension, as evidenced by family studies showing that 
premature onset of hypertension among fi rst degree relatives 
yielded a remarkable high risk of 3.8 times to develop this disorder 
[1]. However, it remains unclear how many genes or which genetic 
determinants might constitute such hereditary background. Th e 
gene encoding endothelial Nitric Oxide Synthase (eNOS) is regarded 
as one of the potentially logical candidate for hypertension, since 
its enhanced production or enzyme bioavailability can lead to the 
constitutive release of nitric oxide in endothelial cells, which exerts 
vaso protective eff ects in Blood Pressure (BP) regulation [2].
Th e clinical cluster of typical anginal chest pain, a positive 
response to stress testing and angiographically normal coronary 
arteries is relatively common in patients with systemic hypertension. 
Functional and structural mechanisms aff ecting the coronary 
microcirculation are oft en responsible for micro vascular angina in 
patients with hypertension.
Capillary rarefaction and left  ventricular hypertrophy are common 
structural abnormalities responsible for micro vascular dysfunction 
in hypertension. Th e higher prevalence of micro vascular angina in 
women than in men, and its relation to menopausal status have led 
to the suggestion that estrogen defi ciency may play a pathogenic role 
in the subgroup of peri- and post-menopausal women with angina 
and hypertension [3,4]. Similar considerations also apply to arterial 
hypertension, the incidence of which increases greatly in women 
aft er the menopause. Th e link between estrogen defi ciency and the 
development of micro vascular angina and hypertension is complex 
and includes abnormal endothelial function, altered autonomic 
nervous system responses and the activation of the Renin Angiotensin 
Aldosterone System (RAAS) [4].
Patients with HTN and micro vascular angina [4,5] oft en show 
slow fl ow and tortuous coronary arteries, suggestive of small vessel 
“obstruction”. Moreover, there is a complex relation among insulin 
sensitivity, hypertension, and endothelial function. Although there 
are few prospective data on the relation between insulin levels and 
the development of hypertension, there is some evidence that insulin 
resistance precedes the onset of established hypertension in high risk 
patients. Because insulin is a vasodilator, it would need to activate a 
variety of other potential physiologic mechanisms to play a causal role 
in the pathogenesis of hypertension. Th ere are changes in the arterial 
wall in patients with hyperinsulinemia, and characteristic decreases 
in elasticity of the arterial wall have been noted in hypertensive 
patients with insulin resistance. Hyperglycemia, hyperinsulinemia, 
and hypertriglyceridemia appear to jointly contribute to increased 
arterial stiff ness. Th ere are, however, ethnic and racial disparities 
in the association of insulin, insulin sensitivity, and blood pressure, 
as this relation is not strongly observed in the black population in 
the United States and elsewhere. Th is may refl ect complex relations 
among obesity, diabetes, and hypertension, which are more common 
in patients with African ancestry [6].
Pathogenesis mechanisms
Th e mechanisms underlying angina pectoris in essential arterial 
Hypertension Patients (HTN) without obstructive Coronary 
Artery Disease (CAD) are still largely unknown. Several functional 
pathophysiological abnormalities have been reported in these patients 
and have been postulated to represent the pathogenic basis for angina 
in these patients, including endothelial dysfunction, increased 
sympathetic tone, micro vascular spasm, estrogen defi ciency, 
psychological disorders, and increased pain sensitivity. Furthermore, 
hypertensive patients have a higher likelihood of presenting with 
features of the metabolic syndrome, e.g., hypertension, dyslipidemia, 
obesity and insulin resistance, compared with the general population 
(30% versus 8%, respectively) [6,7]. Th is occurs more frequently in 
postmenopausal women. Insulin resistance, therefore, may represent 
an important mechanism for vascular dysfunction in this setting [8]. 
Structural abnormalities are also important, i.e., capillary rarefaction 
[9] as well as medial hypertrophy and/or fi brosis of arteriolar vessels. 
Myocardial ischemia triggered by functional and/or anatomical 
abnormalities in the coronary microcirculation has been documented 
in many studies using radionuclide Myocardial Perfusion Imaging 
(MPI) techniques as well as stress induced alterations of cardiac high 
energy phosphate, as assessed by magnetic resonance spectrometry 
[10,11].
In summary, both coronary micro vascular spasm and/or a 
reduced micro vascular vasodilator capacity have been demonstrated 
to cause myocardial ischemia and anginal symptoms in patients with 
hypertension and micro vascular angina.
ABSTRACT
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The pivotal role of endothelial Nitric Oxide Gene (eNOS) 
Allele 
Although there are many genes responsible for the development 
of HTN and diff erent polymorphisms of eNOS gene, we observed 
an important polymorphism of eNOS gene since 2004. In this study, 
Myocardial Perfusion Imaging (MPI) and coronary angiography was 
performed for 60 consecutive hypertensive patients complaining of 
chest pain, whom are admitted at our critical care department at 
Tanta University Hospital11. We revealed that 15 patients had chest 
pain with true ischemia and reversible myocardial perfusion defects 
(multiple and mild) but normal epicardial coronary arteries (micro 
vascular angina), while 15 patients had signifi cant CAD, and 20 
hypertensive patients showed normal perfusion scan and coronary 
angiography. In conclusion; this study revealed that, the prevalence 
of the NOS G298 allele was higher in the hypertensive group with 
microvascular angina (documented by MPI) than it was among the 
control participants (p < 0.005). In addition, we found that eNOS 
allele was signifi cantly higher in the hypertensive group than in 
the control participants, but there was no signifi cant diff erence in 
homozygote mutants among hypertensive participants, x-syndrome 
and patients with CAD [11] (fi gure 1).
Similarly, a recent meta-analyze of three eNOS widely evaluated 
polymorphisms was demonstrated and they include G894T 
(rs1799983) in exon 7, 4b/a in intron 4, and T2786C (rs2070744) 
in promoter region, in association with hypertension from both 
English and Chinese publications, while addressing between 
study heterogeneity and publication bias [12]. Th e investigators 
of this meta-analysis, ascertained the role of eNOS G894T and 
4b/a polymorphisms on hypertension in Asians, and T2786C 
polymorphism in white population [12].
Micro vascular disease in systemic hypertension 
Patients with systemic hypertension oft en experience chest pain 
despite the absence of obstructive coronary artery disease, which is 
caused by coronary micro vascular dysfunction. Structural coronary 
micro vascular abnormalities such as capillary rarefaction and 
functional mechanisms such as endothelial dysfunction are common 
causes for the development of angina pectoris in hypertensive 
individuals [13]. 
Th e presence of endothelial dysfunction in patients with 
hypertension and microvascular angina has been suggested by a 
reduced coronary fl ow response to acetylcholine or atrial pacing 
and by inappropriate endothelial vasoconstrictor activity, mainly 
mediated by Endothelin-1 (ET-1) production [10]. Both coronary 
and peripheral micro- vascular dysfunction have been demonstrated 
in hypertensive patients with chest pain, normal appearing coronary 
angiograms, and no left  ventricular hypertrophy by echocardiography. 
Angina may occur in patients with arterial hypertension in the 
absence of epicardial coronary artery disease due to an abnormally 
elevated resistance of the coronary microvasculature [4,13].
Although impaired micro vascular function and structure is 
generally considered to be the consequence of high blood pressure 
levels, there is evidence that micro vascular changes, i.e., capillary 
rarefaction, and endothelial dysfunction may anticipate the clinical 
onset of arterial hypertension. Th is is supported by the fi nding of 
decreased capillary density in borderline hypertensive subjects and 
even in the normotensive off spring of hypertensive parents as well as 
the presence of endothelial dysfunction in the normotensive off spring 
of hypertensive patients [13].
Hypertension and coronary artery disease (Macro 
Vascular Disease)
High blood pressure is a major modifi able risk factor for all clinical 
manifestations of Coronary Artery Disease (CAD). In people without 
known cardiovascular disease, the lowest systolic (down to 90-114 
mmHg) and the lowest diastolic (down to 60-74 mmHg) pressures 
are associated with the lowest risk for developing CAD. Although 
diastolic blood pressure is the strongest predictor of CAD in younger 
and middle aged people, this relationship becomes inverted and pulse 
pressure shows the strongest direct relationship with CAD in people 
above 60 years of age [14].
Pathophysiological mechanisms of blood pressure as a risk factor 
for CAD are complex and include the infl uence of blood pressure as a 
physical force on the development of the atherosclerotic plaque, and 
the relationship between pulsatile hemodynamics/arterial stiff ness 
and coronary perfusion. Treatment of arterial hypertension has been 
proven to prevent coronary events in patients without clinical CAD. 
Recent studies suggest that a lower systolic blood pressure may be 
appropriate, whereas caution is advised with diastolic blood pressure 
below 60 mmHg [14].
Th e risk of CAD events in hypertensive patients further increase 
in the presence of dyslipidemia. High cholesterol level, the major 
modifi able risk factor for heart disease, has both an environmental 
as well as a genetic component (mutations in the LDL receptor, 
ApoB, PCSK9, and ApoE genes) [15]. Familial Hypercholesterolemia 
(FH) is characterized by isolated elevation of plasma low density 
lipoprotein cholesterol and is associated with high risk of premature 
cardiovascular disease. Premature CAD in the presence of 
hypercholesterolemia might be due to an unhealthy lifestyle alone or 
due to genetic factors in combination with an unhealthy lifestyle [15].
Atherosclerosis in the eras of ancient Egypt 
Defi nite or probable atherosclerosis was present in mummies 
who lived during virtually every era of ancient Egypt, which published 
recently in JACC as the “Horus study”16, a time span of 2,000 years. 
Th e investigators performed whole body, Multi Slice Computed 
Tomography Scanning (MSCT) on 52 ancient Egyptian mummies 
from the Middle Kingdom to the Greco Roman period to identify 
cardiovascular structures and arterial calcifi cations. Th e estimated age 
at the time of death was measured from the computed tomography 
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Figure 1: Diagrams showing the frequency of mutation among studied groups: 
Nitric oxide synthase gene G298 allele: Is it a marker of microvascular angina 
in hypertensive population? Abbreviations:  Co (control), Hy (Hypertension), 
X-(X-Syndrome / microvascular disease), CAD (Coronary Artery Disease), 
IHD (Ischemic Heart Disease) and Tot (Total) (Taken from reference 11). 
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skeletal evaluation. Adel Allam and his colleagues16 reported 
forty-four of 52 mummies had identifi able Cardiovascular (CV) 
structures, and 20 of these had either defi nite atherosclerosis (defi ned 
as calcifi cation within the wall of an identifi able artery, n = 12) or 
probable atherosclerosis (defi ned as calcifi cations along the expected 
course of an artery). Calcifi cations were found in the aorta as well as 
the coronary, carotid, iliac, femoral, and peripheral leg arteries. Th e 
20 mummies with defi nite or probable atherosclerosis were older at 
time of death (mean age 45.1 +/- 9.2 years) than the mummies with 
CV tissue but no atherosclerosis (mean age 34.5 +/- 11.8 years, p = 
0.002). Two mummies had evidence of severe arterial atherosclerosis 
with calcifi cations in virtually every arterial bed. Defi nite coronary 
atherosclerosis was present in 2 mummies, including a princess who 
lived between 1550 and 1580 BCE. Th is fi nding represents the earliest 
documentation of coronary atherosclerosis in a human [16] (Figure 
2). 
Interestingly, the investigators of Horus study16 demonstrated an 
evidence of atherosclerosis in almost all the dynastic eras of ancient 
change of HTN. Probably, repetitive ischemic insults due to macro-
vascular and micro-vascular abnormalities and interstitial fi brosis 
cause an early intrinsic depression of subendocardial longitudinal 
fi ber contractility in these patients, especially in those who have 
hypertrophic hearts. For this reason, longitudinal myocardial 
performance is impaired at an early stage in patients with HTN. In 
addition, in the fi rst stage of the disease the sparing of circumferential 
fi bers results in Ejection Fraction (EF) remaining within the normal 
range [17] (Figure 3).
Th us, GLS provides additional information in the evaluation 
of LVH and myocardial ischemia in HTN, and regional changes in 
Figure 2: Atherosclerosis in Ancient Egyptian Mummies from the ‘Horus 
Study. Multi-slice CT coronary angiography  showed extensive calciﬁ cation 
of right coronary artery and left anterior descending coronary artery, aorta 
and iliac arteries in young Egyptian king who died at his 3rd decade of life. 
Taken from reference [16] and permission was granted from Dr. Adel Allam, 
corresponding author of the ‘Horus Study’.
Egypt. Th e prevalence of modern day risk factors for atherosclerosis 
in ancient Egypt is challenging to estimate. Tobacco was unavailable, 
and without modern transportation, an active lifestyle was likely, 
but the incidence of hypertension and diabetes mellitus is unknown. 
Although the diet of a particular ancient Egyptian with or without 
atherosclerosis is diffi  cult to ascertain, hieroglyphic inscriptions 
on Egyptian temple walls indicate that beef, sheep, goats, wildfowl, 
bread, and cake were regularly consumed suggested that the ancient 
Egyptian diet may have been atherogenic (high in saturated fat), 
particularly among the clergy who consumed the ritual feasts left  by 
families mourning their deceased relatives.
Cardiac imaging in systemic hypertension complaining 
of chest pain
Identiﬁcation of myocardial ischemia among hypertensive 
population is recommended to reclassify patients who are at risk. 
Non-invasive CV imaging is progressively being used and continues 
to provide new technological opportunities to CAD (Macro vascular) 
and micro vascular dysfunction evaluation at early stage. 
Echocardiography and deformation imaging resting 
study
Diabetes and hypertension are two major risk factors which are 
oft en associated with the impairment of Global Longitudinal Systolic 
Strain (GLS), GLS are also common fi ndings in patients with Heart 
Failure with Preserved Ejection Fraction (HFpEF) and it is now well 
known that Left  Ventricular Hypertrophy (LVH) is the key structural 
 
(A) (B)
Figure 3: A. Systolic strain measured in apical LAX view showing depressed 
peak systolic strain and evidence of Post Systolic Shortening (PSS) at mid 
and basal segments of posterior lateral LV wall in Acute Coronary Syndrome 
(ACS) patient, CAG should evidence of subtotal circumﬂ ex coronary artery. 
B. Global longitudinal systolic strain STE of HTN patients with normal EF, 
although his GLS was depressed (-14%). 
longitudinal strain seem to identify specifi c myocardial deformation 
patterns for some forms of myocardial hypertrophy [18]. It is clear 
nowadays that myocardial fi ber mechanical dysfunction precedes 
histopathological changes such as fi brosis and hypertrophy in 
essential hypertension which can be detected in the preclinical stage 
of the disease, through a reduced tissue Doppler derived systolic and 
diastolic velocities and depressed GLS either before or even without 
the development of LVH [17-19].
Stress imaging studies in HTN patients with suspected 
CAD 
Myocardial Perfusion Imaging (MPI); Single Photon Emission 
Computed Tomography (SPECT); Stress Echocardiography (SE); 
Cardiac Magnetic Resonance Imaging (CMR).
Myocardial ischemia ESC guidelines, recommend the search for 
myocardial ischemia in hypertensive patients with suspected history 
of CAD. Diagnosis of myocardial ischemia in hypertensive patients 
is particularly challenging because HTN substantially lowers the 
specifi city of exercise ECG and perfusion scintigraphy [19,20]. When 
exercise ECG is either uninterpretable or ambiguous, an imaging 
test of inducible ischemia by functional study such as perfusion 
scintigraphy [21], SE [22], or stress CMR [23], is warranted. Among 
the imaging tests, stress echo has been shown to have higher specifi city 
but reduced sensitivity compared with SPECT imaging [24]. In 
fact, stress induced wall motion abnormalities are highly specifi c 
for detecting epicardial coronary artery stenosis angiographic ally, 
whereas myocardial perfusion abnormalities are frequently detected 
in hypertensive patients with normal coronary arteries and coronary 
micro vascular disease angiographically (Figure 4,5). Use of dual echo 
imaging of regional wall motion and Coronary Flow Reserve (CFR) 
(normal values > 2) on left  anterior descending artery to distinguish 
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epicardial coronary stenosis from isolated coronary microcirculatory 
dysfunction (reduced CFR without wall motion abnormalities) has 
been proposed. Stress CMR is a valuable option to assess myocardial 
ischemia in HTN patients and should be considered when stress 
echocardiography is expected to be sub optimal due to poor window 
[25]. Figure 5 shows SPECT Myocardial Perfusion Imaging, STE and 
CMR.
reclassify patient’s risk.
Although echocardiography and allied techniques (MSCT, CMR, 
MPI) are the second line study in the evaluation of hypertensive 
patients, it gives many clues suggesting poor prognosis associated with 
hypertension, including LVH, decreased LV systolic function, impaired 
LV diastolic function, and increased left  atrial size and impaired systolic 
function. Along with conventional echocardiographic methods, tissue 
Doppler imaging, three dimensional echocardiography, SE and GLS 
speckle tracking echocardiography are emerging echocardiographic 
modalities in the evaluation of hypertensive patients in the current 
echocardiographic laboratories. Understanding conventional and 
newer echocardiographic parameters is important in the diagnosis 
and assessment of cardio vascular risk in hypertensive patients.
Recommendations of echocardiography in the current 
hypertension guidelines
In the 2013 ESH/ESC Guidelines for the management of arterial 
hypertension, echocardiography is the second line study based on 
medical history, physical examination, and fi ndings from routine 
laboratory tests [28]. Th e guidelines recommended performing 
echocardiographic examination in patients who are suspected 
with having Left  Ventricular Hypertrophy (LVH), Left  Atrial (LA) 
dilatation, or Concomitant Heart Diseases (CAD).
Advances in echocardiography and CMR techniques over the 
last decade have provided new insights into the morphological 
and pathophysiological changes associated with Hypertensive 
Heart Disease (HHD). Comprehensive assessment of systolic and 
diastolic function provides prognostically relevant data. CMR is a 
particularly attractive imaging technique, provides the most accurate 
and reproducible measures of LV function and mass, and enables 
myocardial fi brosis assessment which could identify patients at 
risk of serious cardiac arrhythmias and sudden arrhythmic death. 
In addition, CMR is the most reliable means of distinguishing 
hypertension related LVH from other causes and can also be used to 
screen for secondary causes of systemic hypertension [29].
Cardiac impact of hypertension therapy LVH regression 
LVH represents an important end organ consequence of 
hypertension. Population based studies using echocardiography 
have demonstrated hypertrophy to be closely linked with adverse 
events [30], including stroke, renal impairment, left  ventricular 
dysfunction, atrial and ventricular arrhythmias, and sudden cardiac 
arrhythmia or premature death [31]. Th e eventual development of 
complications from LVH represents long term eff ects that are too 
fi nal to guide clinical therapy, and too slow as a research outcome. 
Th erefore, LVH has been proposed as a surrogate marker of outcome. 
LVH has been shown to be reversed or prevented by a variety of 
haemodynamic, non haemodynamic and pharmacological factors 
[32]. While reductions in the ventricular mass have been associated 
with improved outcome across populations, in studies which identify 
regression of hypertrophy on an individual basis, large populations 
are required to overcome the variability of these measurements. Th us, 
while the association between LVH regression and improved outcome 
has now been recognized in a number of studies [33]. Th is role of 
echocardiography in accurate detection of LVH and its regression 
is great and defi nitely may be improved by the enhancement and 
clinical use of 3DE, which has been validated against CMR [34]. 
Moreover, LVH occurs in 36-41% of hypertensive subjects [35], 
but hypertension is not the only cause of this problem. Hypertrophy 
                (A) (B) 
Figure 4: A. Stress echocardiography in HTN patient with severe LVH in 
parasternal, apical 4 chamber, apical 2 chambers and apical 3 chambers 
views.
B. Myocardial Contrast Echocardiography (MCE) of a patient presented at 
our chest pain unit with acute chest pain without cardiac enzyme biomarkers 
elevation.
 
(A) (B)
Figure 5: Diagrams showing longitudinal strain by 3D speckle-tracking 
echocardiography in a patient with acute myocardial infarction on the day PCI 
of an occluded LAD followed by late enhancement CRM. Images in (A) show 
endomyocardial scar matching STE and MPI in (B).
MSCT coronary angiography
Coronary artery calcium is recognized as an independent 
predictor of CV events and mortality, whereas absence of coronary 
calcium is associated with a very high negative predictive value [26]. 
Yet the role for risk stratifi cation of uncomplicated HTN is not well 
defi ned. In fact, the inclusion of coronary calcium into prediction 
models mainly improves risk stratifi cation of hypertensive patients 
at intermediate risk (SCORE risk between 5 and 10%), whereas little 
value has been demonstrated in patients at low risk [27].On the other 
hand, the limited availability, costs, and radiation exposure (±1 mSv) 
represent substantial limitations to wide spread implementation of 
coronary calcium evaluation in clinical practice.
Clinical implications of cardiac imaging on health care 
and “HTN patients” management
Th e correct diagnosis of hypertension and precise assessment of 
cardiovascular risk are essential to give proper treatment in patients 
with hypertension. Risk stratifi cation in HTN patients is of crucial 
importance to properly manage patients at increasing risk and prevent 
adverse events. A symptomatic involvement of diff erent organs in 
HTN patients represents an independent determinant of CV risk and 
the identifi cation of target organ damage is recommended to further 
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may be infl uenced by obesity, diabetes, the metabolic syndrome, 
and renal impairment, among other etiologies. Progression of the 
condition may lead to ischemia, both due to concurrent CAD as well 
as failure of vascular proliferation to match myocardial proliferation, 
vascular compression, and the eff ect of raised LV pressure on 
subendocardial fl ow (relative ischemia) or even MVD. Hence, the 
role of non-invasive cardiac imaging is crucial in order to identify the 
etiology of myocardial ischemia in such patient’s population.
Investigation of chest pain symptoms 
Chest pain in patients with hypertension may signify concurrent 
CAD or may simply refl ect sub endocardial ischemia due to LV 
hypertrophy and increased aft erload. Th e diagnosis of CAD has 
particular challenges in this setting, because ‘false positive’ results may 
occur when sub endocardial ischemia causes abnormal stress ECG or 
myocardial perfusion scan in the absence of fl ow limiting epicardial 
coronary disease [36]. A normal stress electrocardiogram, performed 
to a high workload, has a high negative predictive value, but an 
abnormal or ambiguous test warrants further evaluation. Th ere is 
some evidence in favor of preferential use of stress echocardiography 
for this purpose, because stress induced wall motion abnormalities 
are highly specifi c for CAD, while perfusion defects (MPI) in 
hypertensive patients may arise from abnormal myocardial fl ow 
reserve not due to epicardial coronary disease [37].
Role of echocardiography in decision to initiate treatment
Eff ects of antihypertensive agents on Left  Ventricular Mass 
(LVM) and other echocardiographic surrogate endpoints (e.g. LA 
size and diastolic function) have been extensively studied. Several 
large studies sponsored by the National Institutes of Health and the 
US Veterans Administration Cooperative Studies program have 
evaluated the eff ects of antihypertensive mono therapy. In general, 
it appears likely that there are diff erences between the effi  cacy of 
antihypertensive drugs and their eff ects on LVH. LVH regression 
does not adversely aff ect cardiac function and may be associated with 
improvements in diastolic function. However, although the fi nding 
of increased LVM on echocardiography could potentially guide 
selection of initial or intensity of therapy in hypertensive patients, 
JNC 7 recommendations do not risk stratify patients for treatment on 
the basis of target organ damage. Current guidelines recommend the 
use of combination treatment to get blood pressure to goal, thus blood 
pressure remains the primary target of therapy. A part of the problem 
with getting a more central role for echocardiography to guide 
therapy is that despite the adverse prognosis associated with LVH in 
hypertension, there are inconsistent data from numerous studies that 
have evaluated the comparative effi  cacy of specifi c antihypertensive 
agents in LVH regression, as well as survival benefi ts associated 
with LVH regression. In a meta-analysis of trials of antihypertensive 
therapy, angiotensin converting enzyme inhibitors were the most 
eff ective agents, leading to a 13.3% reduction in LVM compared 
with 9.3% for calcium channel blockers, 6.8% for diuretics, and 5.5% 
for beta blockers [38]. However, in a comparison of Enalapril and 
long acting nifedipine in patients with essential hypertension, the 
PRESERVE (Prospective Randomized Enalapril Study Evaluating 
Regression of Ventricular Enlargement) trial, systolic and diastolic 
pressures, as well as LVM were reduced to a similar degree with both 
agents [39]. On the other hand, the LIFE (Losartan Intervention For 
Endpoint Reduction in Hypertension) trial echocardiographic sub 
study demonstrated superior LVM reduction (21.7 g/m2 ) in patients 
treated with the angiotensin receptor blocker losartan compared 
with those treated with the beta blocker atenolol (17.7 g/m2 ) [40]. 
Finally, despite a 20% incidence of LVH regression with placebo, 
diuretic therapy with chlorthalidone and hydrochlorthiazide, 
respectively, demonstrated greater LVH regression over alternative 
agents in both the TOMHS (Treatment of Mild Hypertension Study) 
and Department of Veterans Aff airs Cooperative Study Group on 
Antihypertensive Agents [41,42].
In summary, echocardiography may be helpful in several scenarios. 
Patients with hypertensive heart disease who become symptomatic 
require follow-up echocardiography to evaluate systolic and diastolic 
function. Dissociation between blood pressure measurements and LV 
hypertrophy is an indication for further testing. On the other hand, 
stress echocardiography or MPI showed be performed for evaluation 
of the nature of chest pain in hypertensive patients with LVH. 
Genetic testing in HTN patients
Studies involving adoptive families and twins have demonstrated 
the genetic basis of hypertension and shown that genetic factors 
account for about 40% of the variance in blood pressure among 
individuals. Arterial hypertension is genetically complex: Multiple 
genes infl uence the blood pressure phenotype through allelic eff ects 
from single genes and gene interactions. Moreover, environmental 
factors also modify the blood pressure phenotype. Th is complexity 
explains why the identifi cation of the underlying genes has not 
been as successful in hypertension as in other diseases (such as type 
1 and type 2 diabetes mellitus). Th e identifi cation of the genetic 
determinants of hypertension has been most successful in endocrine 
forms of hypertension, which have well defi ned phenotypes that 
permit a precise patient stratifi cation into homogeneous cohorts [43].
Research has shown that genetic factors contribute signifi cantly 
to the susceptibility of developing hypertension [44-47]. A study 
of Caucasian and African American children revealed the T235 
allele on the angiotensinogen gene to be more common in African 
American children compared to Caucasian. Th is is meaningful such 
that the T235 allele is positively correlated with increased serum 
angiotensinogen levels and hypertension in African American boys 
and girls, when compared to Caucasian children (p < 0.01) [48]. 
Other groups addressing African Americans have found that Single 
Nucleotide Polymorphisms (SNPs) on SLC4A5, a sodium bicarbonate 
transporter gene found on chromosome 2, were also signifi cantly 
associated with hypertension [49,50].
A promising area for the application of genetic testing to 
personalized medicine is the prediction of responses and adverse 
reactions to antihypertensive drugs.
CONCLUSION
Patients with systemic hypertension oft en experience chest pain 
despite the absence of obstructive coronary artery disease, which 
is caused by coronary micro vascular dysfunction. eNOS gene 
polymorphism is proved to be an important etiology in micro vascular 
angina (x-syndrome) among hypertensive patients. In addition, the 
eNOS mutant gene showed a signifi cant increase in isolated HPN 
and in patients with CAD as well. Th e major cardiovascular risk 
factors responsible for small vessel disease (micro-vascular) are 
similar for those attributable to CAD (macro-vascular) in systemic 
hypertension. Repetitive ischemic insults in HTN patients due to 
macro-vascular and micro-vascular abnormalities and interstitial 
fi brosis can cause an early intrinsic depression of sub endocardial 
longitudinal fi ber contractility and this can be detected clearly non-
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invasively by GLS speckle tracking echocardiography. Similarly, 
microvascular dysfunction can be demonstrated with great certainty 
by MPI. Currently, non-invasive cardiac imaging is being increasingly 
used, and innovative imaging techniques are on the way that might 
further refi ne risk stratifi cation of hypertensive patients and provide 
opportunities to better target therapeutic strategies.
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